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Abstract
Background: Androgenic alopecia (AGA) is a major type of human scalp hair loss, which is caused by two androgens:
testosterone (T) and 5α-dihydrotestosterone (5α-DHT). Both androgens bind to the androgen receptor (AR) and induce
androgen-sensitive genes within the human hair dermal papilla cells (HHDPCs), but 5α-DHT exhibits much higher
binding affinity and potency than T does in inducing the involved androgen-sensitive genes. Changes in the induction
of androgen-sensitive genes during AGA are caused by the over-production of 5α-DHT by the 5α-reductase (5α-R)
enzyme; therefore, one possible method to treat AGA is to inhibit this enzymatic reaction.
Methods: RT-PCR was used to identify the presence of the 5α-R and AR within HHDPCs. A newly developed
AGA-relevant HHDPC-based assay combined with non-radioactive thin layer chromatography (TLC) detection
was used for screening crude plant extracts for the identification of new 5α-R inhibitors.
Results: HHDPCs expressed both 5α-R type 1 isoform of the enzyme (5α-R1) and AR in all of the passages used
in this study. Among the thirty tested extracts, Avicennia marina (AM) displayed the highest inhibitory activity at the
final concentration of 10 μg/ml, as the production of 5α-DHT decreased by 52 % (IC50 = 9.21 ± 0.38 μg/ml).
Conclusions: Avicennia marina (AM) was identified as a potential candidate for the treatment of AGA based on its
5α-R1-inhibitory activity.
Keywords: Androgenic alopecia, 5α-reductase inhibitory activity, Human hair dermal papilla cell-based assay,
Anti-androgenic activity, Avicennia marina
Background
Androgenic alopecia (AGA) is a major type of scalp hair
loss in both males and females that is becoming a world-
wide issue. AGA is caused by androgens, namely, testos-
terone (T) and 5α-dihydrotestosterone (5α-DHT). T is the
major circulating androgen and is converted to 5α-DHT
by the 5α-reductase enzyme (5α-R) [EC 1.3.99.5], which is
present in two isoforms i.e., 5α-reductase type 1 (5α-R1)
and 5α-reductase type 2 (5α-R2) [1–6]. Both androgens
bind to the androgen receptor (AR), forming a receptor-
ligand complex that is translocated to the nucleus, where
it acts as a transcription factor in regulating androgen-
sensitive genes [7]. However, 5α-DHT exhibits five times
higher binding affinity and 10-fold higher potency than T
in inducing androgen-sensitive genes. The products of
these androgen-sensitive genes act as growth factors, af-
fecting hair growth [3, 5, 7–17]. During AGA, overproduc-
tion of 5α-DHT causes the down-regulation of growth
factors, which results in the shortening of anagen/growth
phase. This shortening causes the miniaturisation of large,
thick-pigmented terminal hair to small, fine, un-
pigmented vellus hair with a diameter of less than
0.03 mm [1, 2].
Currently, minoxidil and finasteride are the two
FDA-approved synthetic drugs used to treat AGA [18].
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Minoxidil, a vasodilator and potassium channel opener,
prolongs the anagen phase and converts vellus hair to ter-
minal hair [19, 20]. However, minoxidil is only effective on
30-35 % of patients, and the treatment must be continued
for life [18]. In addition, the side effects of 2 % and 5 %
minoxidil solution include scalp irritation, pruritus,
dryness, scaling, itchiness, redness, contact dermatitis
and hypertrichosis [21, 22]. Finasteride, a synthetic
azo-steroid, is a 5α-R2 inhibitor that binds irreversibly
to the enzyme and inhibits the conversion of T to 5α-
DHT, thereby reducing the serum 5α-DHT concentration
by 68 % [3]. However, finasteride is effective in only 48 %
of the patients [21] and has the observed side effects of
impotence, abnormal ejaculation, abnormal sexual func-
tion, myalgia, testicular pain and gynecomastia [23].
Because only two synthetic drugs are currently available,
a search for new drugs to treat AGA is necessary. Among
various sources, natural products provide an abundance of
diverse chemical structures, representing a rich source for
lead structures in drug development [18]. Recent studies
have primarily focused on medicinal plants, and many
natural product groups have been demonstrated to have
5α-R inhibitory activity. These include a sterol from
Cuscuta reflexa [24]; fatty acids, including oleic, lauric,
myristic and linoleic acid from Serenoa repens [25]; a
triterpenoid, ganoderic acid from Ganoderma lucidium
[26]; the saponins soyasaponin I and kaikasaponin III
from Pueraria thomsonii [27]; and a catechin, epigallo-
catechin-3-gallate [EGCG] from Camellia sinensis [28]. In
addition, various well-known flavonoids, such as myrice-
tin, quercitin, alizarin, kaempferol, genistein and daidzein,
have also been reported to exhibit inhibitory activity
[28]. However, none of these reports have used dermal
papilla cells for either their cell-based or enzyme-based
(source of 5α-R) assay systems. Dermal papilla cells are
a primary cell type that regulate hair growth, express
5α-R and are the only site of androgen action within
the hair follicle [1, 18]. Therefore, the inhibition of 5α-
R activity in this specific type of cells should have a dir-
ect effect on AGA treatment. Therefore, to obtain an in-
hibitory assay system for this type of hair loss, it is most
relevant and reliable to use hair cells, specifically hu-
man hair dermal papilla cells (HHDPCs).
In this study, a non-radioactive HHDPC-based assay
system, which is highly relevant to the AGA type of hu-
man scalp hair loss, was used to screen plant extracts for
5α-R inhibitory activity. The most potent crude extract
was further tested for the anti-androgenic activity to
evaluate its potential to overcome the effects of andro-
gens on the expression of the aforementioned growth
factors.
Methods
Plant materials and extraction
The list of the Thai plants and plant parts used in this
study is shown in Table 1. All plant materials were pur-
chased from of Chao Krom Poe Dispensary in Bangkok,
Thailand. Voucher specimens of the plants were depos-
ited in the herbarium collection of Thailand’s Forestry
Department with the following specimen numbers (SNs):
Avicennia marina, SN145917; Micromelum minutum,
SN055802; Diospyros mollis, SN142793; Alternanthera ses-
silis, SN097887; Salacia verrucosa, SN099212; Crotalaria
retusa, SN043656; Senna timoriensis, SN094415; Dalbergia
parviflora, SN200944; Afgekia sericea, SN124647; Bacopa
monnieri, SN176524; Tarenna hoaensis, SN176524; Ptery-
gota alata, SN059871; Scoparia dulcis, SN163093; and
Senna garrettiana. SN008620. For preparation of crude ex-
tracts, the plant part used for each species was ground into
powder and extracted through maceration using 100 %
methanol at room temperature for two days. The methano-
lic extracts were then evaporated to dryness at 45 °C using
a rotary evaporator (Buchi, Switzerland) and kept at -20 °C
until used.
Fig. 1 RT-PCR showing the expression of 5α-R and AR in HHDPCs.
A 1 % agarose gel showing, from the top, the expression of 5α-R1
(5α-reductase type 1, 380 bp), AR (androgen receptor, 811 bp), 5α-R2
(5α-reductase type 2, 440 bp) and β-actin (584 bp) within passages
2, 4, 5 and 6 of HHDPCs. The 1-kb DNA ladder (L) shows the band
sizes of 1 kb and 750, 500 and 250 bp from top down
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Chemicals, enzymes and reagents
All of the organic solvents used were analytical grade
and purchased from RCI Labscan (Bangkok, Thailand).
Ultrapure grade dimethyl sulfoxide (DMSO) was purchased
from Ameresco® (Framingham, USA). Testosterone (T) and
5α-dihydrotestosterone (5α-DHT) were purchased from
Sigma-Aldrich (St. Louis, USA). Dutasteride was purchased
from BDG Synthesis (Wellington, New Zealand). Agarose-
LE was purchased from Affymetrix (Santa Clara, USA).
Mesenchymal stem cell medium and its supplements were
purchased from Sciencell Research Laboratories (Carlsbad,
USA). Foetal bovine serum, 100X antibiotic-antimycotic so-
lution, 10X PrestoBlue®, RPMI medium, 50X Tris-acetate-
EDTA (TAE) buffer, 0.25 % trypsin-EDTA and Platinum®
Taq polymerase were purchased from Invitrogen (Grand
Island, USA). A GeneRuler 1-kb DNA ladder was purchased
from Thermo Fisher Scientific (Pittsburgh, USA). RNeasy®
mini kits were purchased from Qiagen (Valencia, USA).
DNase I enzyme, first-strand cDNA synthesis kit, dATP,
dTTP, dCTP and dGTP were purchased from Fermentas
(Walthan, USA).
Culturing of human hair dermal papilla cells
HHDPCs, obtained from Sciencell Research Laboratories
(Carlsbad, USA), were grown in mesenchymal stem cell
medium containing 5 % foetal bovine serum (FBS),
mesenchymal stem cell medium supplement and 1X
antibiotic-antimycotic solution at 37 °C in 5 % CO2. The
cells between passages 2 to 6 were used in this study.
Evaluating the presence of 5α-R and AR in HHDPCs
Reverse-transcriptase polymerase chain reaction (RT-PCR)
was used to identify the type of 5α-reductase enzymes (i.e.,
5α-R1 and/or 5α-R2) and AR, expressed in passages 2, 4, 5
and 6 of HHDPCs. Total RNA was extracted from
HHDPCs according to the manufacturer’s instructions for
the RNeasy® mini kit. The RNA was subsequently treated
with DNase I to remove any genomic DNA contamination.
Table 2 Forward and reverse primers and expected sizes of AR, 5α-R enzymes and β-actin
Name Primer pair Expected size (bp)
Androgen receptor (AR) F: 5' CGTGCGCGAAGTGATCCAGAA 3' 811
GenBank:NM_000044.3 R: 5' TGCGCTGTCGTCTAGCAGAGAA 3'
5α-Reductase type 1 (5α-R1) F: 5' ACTGCATCCTCCTGGCCATGTTC 3' 380
GenBank:NM_001047.2 R: 5' GGCATAGCCACACCACTCCATGA 3'
5α-Reductase type 2 (5α-R2) F: 5' AAGCACACGGAGAGCCTGAA 3' 450
GenBank:NM_000348.3 R: 5' GCCACCTTGTGGAATCCTGTAGC 3'
β-actin (internal control) F: 5' ATGATGATATCGCCGCGCTC 3' 584
GenBank:NM_001101.3 R: 5' GCGCTCGGTGAGGATCTTCA 3'
Table 1 List of Thai medicinal plants used in this study
Medicinal plant Abbreviation Family Plant part
Afgekia sericea AS Fabaceae Aerial
Alpinia galangal AG Zingiberaceae Fresh Rhizome
Alternanthera sessilis ASHE Amaranthaceae Whole plant
Avicennia marina AM Acanthaceae Heartwood
Bacopa monnieri BM3 Plantaginaceae Aerial
Balanophora abbreviate BA Balanophoraceae Aerial
Barleria cristata BC Acanthaceae Root
Butea monosperma BM Fabaceae Stem
Centella asiatica CA Mackinlayaceae Aerial
Citrus limonum CL Rutaceae Fresh Peel
Crotalasia retusa CR Fabaceae Root
Dalbergia parviflora DP Leguminosae Heartwood
Derris elliptica DE Leguminosae Stem
Diospyros mollis DM Ebenaceae Stem
Kaempferia galangal KG Zingiberaceae Dried Rhizome
Leersia hexandra LH Poaceae Stem
Maclura cochinchinen MC Moraceae Stem
Micromelum minutum MM Rutaceae Stem
Olendra musifolia OM Oleandraceae Stem
Pterygota alata PA Malvaceae Stem
Randia horrida RH Rubiaceae Root
Salacia verrucosa SV Celastraceae Stem
Scoparia dulcis SD Plantaginaceae Stem
Senna garretiana SG Fabaceae Heartwood
Senna timoriensis ST Fabaceae Stem
Tarenna fragans TF Rubiaceae Leaves
Tarenna hoaensis TH Rubiaceae Stem
Telosma minor TM Asclepiadaceae Stem
Zanthoxylum limonella ZL Rutaceae Stem
Zingiber officinale ZO Zingiberaceae Fresh Rhizome
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Complementary DNA (cDNA) was synthesised from the
treated RNA using the first-strand cDNA synthesis kit. The
cDNA obtained from this reaction was used as a DNA tem-
plate for PCR reactions. The PCR reaction comprised of 1X
PCR buffer, 2 mMMgCl2, 0.4 mM dNTP mix, 0.4 μM each
of forward and reverse primer and 2.5 units of Platinum®
Taq polymerase. The forward and reverse primers for the
two isoforms of 5α-R (5α-R1 and 5α-R2) and AR, shown in
Table 2, were designed based on the protein region of the
full-length sequence obtained from the NCBI GenBank
using Clone manager (Scientific & Educational Software,
USA) and made to order at 1st Base Laboratories (Selangor,
Malaysia). The PCR-thermal profile started with an initial
denaturation at 94 °C for 3 min, followed by 35 cycles of
denaturation at 94 °C for 30 s, annealing for 30 s at 52 °C,
and extension at 72 °C for 2 min, followed by a final exten-
sion at 72 °C for 10 min. The PCR products were analysed
using 1 % agarose gel electrophoresis.
Cytotoxicity testing of methanolic plant extracts on
HHDPCs
For the cytotoxicity test, HHDPCs were seeded at a cell
density of 1x105 cells/ml onto 96-well plates (100 μl of
10,000 cells/well). After 24 h, the cells were separately
treated with 100 μl of 5, 10, 20, and 40 μg/ml of each ex-
tract to obtain the final concentrations of 2.5, 5, 10 and
20 μg/ml, respectively, and 1 % DMSO (control). Cell
viability was measured at 24 h after treatment using 1X
PrestoBlue® reagent in RPMI medium. In the presence of
viable cells, PrestoBlue® changes from a non-fluorescent
blue colour to a fluorescent purple-pink colour, detected
using Multimode Detector DTX 880 (Beckman Coulter®,
Indianapolis, USA), a bottom-read fluorospectrophot-
ometer with excitation/emission wavelengths of 535
and 615 nm, respectively. The highest final non-toxic
concentration of each extract was then used for further
studies.
Screening of plant extracts for 5α-R inhibitory activity
using HHDPC-based assay combined with non-radioactive
TLC detection
HHDPCs were seeded at a cell density of 1x105 cells/ml
onto 96-well plates (100 μl of 10,000 cells/well). After
24 h, the cells were separately treated (in a total volume
of 200 μl) with the final concentrations of 0.1 mM T and
0.5 % DMSO (internal control), 0.1 mM T and 0.25-
20 μg/ml (non-toxic concentrations of the methanolic
plant extracts), and of 0.5 % DMSO as negative control.
After 48 h, the culture medium of each treatment was
collected in Eppendorf tubes, and the attached treated
cells were tested for cell viability using the 1X Presto-
blue® reagent in RPMI medium. The remained substrate
T and the product 5α-DHT formed from the activity of
cellular 5α-R were extracted from the culture medium
using an equal volume of ethyl acetate. The ethyl acetate
layer was dried and reconstituted using 20 μl of metha-
nol and spotted onto a TLC Silica gel 60 F254 aluminium
plate (Merck, Darmstadt, Germany). The TLC plate was
developed using toluene:acetone (8:2) as the mobile
phase [9]. The developed TLC plate was dipped briefly
in a solution of 42.5 % phosphoric acid and heated at
120 °C for 20 min for the visual detection of 5α-DHT
at 366 nm using a TLC Reprostar Imager (Camag,
Switzerland), and the amount 5α-DHT formed was
quantitated by scanning the product band of 5α-DHT
at 366 nm using TLC Densitometer Scanner 3 (Camag,
Fig. 2 Level of cytotoxicity on HHDPCs of various methanolic plant
extracts grouping as (a) highest toxicity (2.5 - 5 μg/ml), (b) moderate
toxicity (>10 μg/ml) and (c) low toxicity (> 20 μg/ml)
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Switzerland) to obtain its value of peak area which was
then converted to the amount of 5α-DHT using a cali-
bration curve. The calibration curve of 5α-DHT was
constructed by plotting peak areas and various amounts
of 5α-DHT which showed linearity from 50 to 500 ng
with the coefficient of determination (r2) value of 0.9874.
The extract of AM displaying the highest potential in inhi-
biting the 5α-R enzyme was studied further to determine
its effects on androgen-sensitive genes.
Statistical analysis
All of the experiments were performed in triplicate, and
the data are shown as the means ± SD. One-way ANOVA
statistical analysis was used, and a P-value <0.05 was
considered to be statistically significant.
Results
Expression of 5α-R1 and AR in HHDPCs
The effect of androgens on hair growth is exerted
through the interactions with 5α-R and AR in HHDPCs.
Therefore, the presence of both the enzyme and the re-
ceptor is important for this study, and expression in
HHDPCs was evaluated. The RT-PCR analysis revealed
that the genes of the Type 1 enzyme, 5α-R1, and AR were
both expressed in passages 2, 4, 5 and 6 of HHDPCs,
whereas the Type 2 gene, 5α-R2, was not expressed in any
of the passages (Fig. 1). β-actin, used as an internal
control, was constantly expressed in all passages.
Cytotoxicity of methanolic plant extracts on HHDPCs
To obtain a suitable starting concentration for screening
methanolic plant extracts for 5α-R inhibitory activity,
Fig. 3 a Cytotoxicity at 2.5-20 μg/ml dutasteride and b its 5α-R1 inhibitory activity at 0.001, 0.01 and 10 μg/ml on HHDPCs showing the inhibition
of 16.5 %, 90.5 % and 100 %, respectively
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the cytotoxicity of each plant extract on HHDPCs at
various concentrations was subsequently tested using
Prestoblue® cell viability reagent. The results revealed
that the extracts, at their final concentrations, exhibited
different toxic levels on the cells (Fig. 2). Above the cell
viability of 85 %, the extracts were considered to be non-
toxic. The plant extracts of DM and SG were the most
toxic, exhibiting toxicity above 2.5 μg/ml, followed by
the ST, ASC and DP extracts, which displayed toxicity
above 5 μg/ml (Fig. 2a). The other extracts with moderate
toxicity above 10 μg/ml were SD, OM, AM and BC
(Fig. 2b), whereas the remaining extracts, including TF,
CA, AS, LH, MF and BM, displayed no toxicity even at
20 μg/ml (Fig. 2c). Based on these results, the highest final
non-toxic concentration of each extract was used for the
subsequent inhibitory activity analyses.
Identification of plant extracts possessing 5α-R1
inhibitory activity using an HHDPC-based assay combined
with non-radioactive TLC detection
As previously mentioned, AGA is induced through the
over-production of 5α-DHT, and the enzyme responsible
for the conversion of T to 5α-DHT within HHDPCs is
5α-R. Thus, one potential method for reducing the effect
of the androgens on hair growth is to inhibit this enzymatic
reaction. HHDPCs expressed only 5α-R1, and therefore,
the assay system was tested using a well-known 5α-R1 in-
hibitor, dutasteride, as a positive control. To obtain the
starting concentration for testing the inhibitory activity,
first, the cytotoxicity of dutasteride for HHDPCs was deter-
mined. It was observed that dutasteride exhibited toxicity
(i.e., cell viability less than 85 %) above the final concentra-
tion of 10 μg/ml (Fig. 3a). At this concentration, the cell-
based assay displayed complete 5α-R1 inhibitory activity
(Fig. 3b). Lowering the concentration of dutasteride to 0.01
and 0.001 μg/ml, the assay displayed the 5α-R1 inhibition
of 90.5 and 16.5 %, respectively, with an IC50 value of
0.005 μg/ml or 9.7 nM (Fig. 3b). The assay system was then
used to screen the methanolic plant extracts for 5α-R1
inhibitory activity. Using the highest final non-toxic
concentration (Table 3) in the incubation mixture, each
individual extract was evaluated for this activity. As
shown in Figs. 4a-4c, each lane represents the inhibitory
potential of each extract at its highest final non-toxic con-
centration. The lane “Cell + T” was the internal control for
the conversion of T to 5α-DHT, and the lane “Cell-T” was
the negative control. Among all extracts screened, the
plant extracts of BM, DM, OM, MC, BC and BA displayed
only 10 % inhibition, whereas the extracts of KG and MM
displayed approximately 20 % inhibition. The highest
inhibitory activity was observed from the crude extract
of AM at a final concentration of 10 μg/ml through the
reduction in 5α-DHT formation by more than 50 %
(Table 3). The IC50 value of AM was determined to be
9.21 ± 0.38 μg/ml.
Discussion
This study focuses on identifying new 5α-R inhibitors
specifically for treating AGA using a newly developed
HHDPC-based assay system. A cell-based assay was chosen
over a cell-free assay, where the 5α-R enzyme has been
Table 3 Percentage of 5α-DHT formation in HHDPCs after being
treated with various methanolic plant extracts (at 10 μg/ml) and
dutasteride (also at 10 μg/ml). The 5α-DHT formed in the standard
bioassay system was set to be 100 %
Plant extracts Abbreviation 5α-DHT formed (% of control)
Internal control + Substrate (T) 100 ± 5
(Assay system) - Substrate (T) 0 ± 0
Positive control Dutasteride 0 ± 0
Avicennia marina AM 48 ± 3
Kaempferia galangal KG 88 ± 7
Micromelum minutum MM 89 ± 3
Butea monosperma BM 89 ± 5
Diospyros mollisa DM 89 ± 4
Olendra musifolia OM 90 ± 9
Barleria cristata BC 91 ± 9
Maclura cochinchinen MC 95 ± 5
Balanophora abbreviate BA 97 ± 4
Alpinia galangal AG 98 ± 3
Randia horrida RH 98 ± 8
Centella asiatica CA 99 ± 1
Derris elliptica DE 99 ± 3
Telosma minor TM 100 ± 4
Zanthoxylum limonella ZL 100 ± 13
Salacia verrucosa SV 101 ± 7.0
Crotalasia retusa CR 101 ± 13
Senna timoriensisb ST 102 ± 10
Citrus limonum CL 103 ± 11
Zingiber officinale ZO 104 ± 13
Dalbergia parviflorab DP 104 ± 15
Afgekia sericea AS 105 ± 3
Bacopa monnieri BM3 105 ± 9
Leersia hexandra LH 106 ± 2
Alternanthera sessilis ASHE 106 ± 12
Tarenna hoaensis TH 107 ± 12
Pterygota alata PA 110 ± 15
Scoparia dulcis SD 116 ± 4
Senna garretianaa SG 116 ± 8
Tarenna fragans TF 117 ± 3
aand bthe extracts used with the highest non-toxic concentrations at 2.5 and
5.0 μg/ml, respectively
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reported to be isolated from the rat liver [9, 26, 29],
prostate [23, 30], epididymis [27] or the human prostate
[24], as the latter does not mimic the actual conditions of
the enzymes and does not take into account the toxicity of
the test compounds [28]. In addition, the reliability of the
cell-free system is presumably low because the sequence
similarities between the 5α-R1 and 5α-R2 from rats and
humans are only 61 % and 75 % [6], respectively, which
might affect the nature of active site formation and hence
the activity. In addition, two isoforms of the enzymes,
5α-R1 and 5α-R2, are specifically distributed in different
organs within the human body [6], and therefore, testing
the enzyme isolated from the human prostate [24] might
not be relevant to the type of enzyme present in human
hair cells.
To obtain a cell-based assay system relevant for hair
loss, it is more appropriate to use hair cells than trans-
fected rat [28] or insect [25] cell lines. These cell lines of
rats, insects and humans possess different levels of tox-
icity tolerance to the test compounds, such that a potent
concentration of 5α-R inhibitor for the rat or insect cell
line might be toxic to human hair cells. Hair comprises
Fig. 4 TLC plates visualised under 366 nm showing the effect of 30 methanolic plant extracts on the enzyme activity of 5α-R1. a Micromelum
minutum – MM, Tarenna hoaensis – TH, Scoparia dulcis – SD, Olendra musifolia – OM, Avicennia marina – AM, Salacia verrucosa – SV, Pterygota alata – PA,
Crotalasia retusa – CR, Bacopa monnieri – BM3, Afgekia sericea- AS. b Barleria cristata – BC, Centella asiatica – CA, Butea monosperma – BM,
Tarenna fragans – TF, Diospyros mollis – DM, Senna garretiana – SG, Telosma minor – TM, Balanophora abbreviate – BA, Zanthoxylum limonella –ZL,
Senna timoriensis – ST. c Maclura cochinchinen – MC, Alternanthera sessilis (hexane extract) – ASHE, Leersia hexandra – LH, Alpinia galangal – AG, Citrus
limonum – CL, Dalbergia parviflora – DP, Kaempferia galangal – KG, Derris elliptica – DE, Randia horrida – RH, Zingiber officinale – ZO. The internal
(Cell + T) and negative (Cell-T) controls are shown in the middle and right-hand side of the plate, respectively
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at least fifteen distinct types of cells where the dermal
papilla cell is a primary cell type that regulates hair
growth, expresses 5α-R and is the only site of androgen
action [1, 12, 18]. Therefore, human hair dermal papilla
cells (HHDPCs) were used as a model for the identifica-
tion of potent 5α-R inhibitors in this study. After 48 h of
T treatment on HHDPCs in our optimised incubation
mixture, the enzymatic product, 5α-DHT, was detectable
and measurable on a TLC plate at 366 nm (Fig. 4) by
simply dipping the developed TLC plate into 42.5 %
phosphoric acid solution, heating it at 120 °C for 20
mins and quantitatively analysing it using Camag Scan-3
TLC densitometer. The sensitivity of this TLC detection
is in the range of ng level (from 25 to 250 ng). Under
the normal condition of our cell-based assay which is in
the presence of 5.8 μg of T (0.1 mM final concentration),
it appears that HHDPCs (10,000 cells) present in the in-
cubation mixture can convert T into 87 ng of 5α-DHT.
In the presence of a positive crude extract such as AM,
the amount of 5α-DHT formed was reduced to 42 ng,
equivalent to 48 % of the conversion (Table 3), which is
still in the detectable range.
Therefore, with the high sensitivity of detection, there
is no need to use radioactively labelled T and complicated
detectors as previously reported, such as a radioactive
image analyser [26, 30], TLC radioactive scanners [28],
HPLC radioactive detectors [25] or measuring the de-
crease in radiolabelled T concentration at 254 nm using
HPLC [9, 23, 24, 27].
The RT-PCR results revealed the expression of only
5α-R1 (Fig. 1), which is consistent with the results of
previous studies [6, 31–33]. Therefore, the non-radioactive
HHDPC-based assay system was first evaluated with a
positive control, dutasteride, which is a well-known specific
5α-R1 inhibitor [6]. The compound demonstrated complete
inhibition of the enzyme activity at a final concentration of
10 μg/ml with an IC50 value of 9.7 nM (Fig. 3). The assay
system was then used for screening thirty methanolic plant
extracts for 5α-R1 inhibitory activity. Among the tested ex-
tracts (Fig. 4a-c), it appeared that only the heartwood meth-
anolic extract of Avicenna marina (AM) at the final
concentration of 10 μg/ml exhibited the highest potential
for inhibiting the enzyme activity, as the 5α-DHT produc-
tion was reduced to 48 % (Table 3). The rest of the crude
extracts were found to have low or negative inhibitory
effect (i.e., ranging from -10 to 20 %) compared with
the internal control. To avoid false positive results, the
attached treated cells in the 96-well plate were tested
for their viability. The cells treated with 10 μg/ml of
AM and 10−4 M of T for 48 h displayed 100.5 ± 2.02 %
(n = 3) viability relative to the internal control, confirming
the positive effect of the AM extract.
For information about Avicenna marina (AM), this
plant is commonly called grey or white mangrove. It is a
species of mangrove trees belonging to the Acanthaceae
family and has been traditionally used in Egypt to cure
skin diseases [34]. Phytochemically, terpenoids and ste-
roids, such as lupeol, botulin, β-sitosterol and betutinic
acid, have been identified from the bark of AM [34].
Whether any of these compounds are the active 5α-R1
inhibitors is still unknown. Therefore, activity-guided
fractionation is currently being conducted to identify the
active compounds in the AM extract.
Conclusions
The use of a non-radioactive HHDPC-based assay system
in this study has led to the identification of Avicennia
marina (AM) as a new potential candidate for the treat-
ment of AGA.
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